Potentiation of the antidepressant-like effect of fluoxetine by aripiprazole in the mouse tail suspension test

Journal of Pharmacological Sciences

Volumn 108, Issue 3, 2008, Pages 381-384

  Kamei, Junzo ^a   Miyata, Shigeo ^a   Sunohara, Takayuki ^a   Kamei, Atsuko ^b   Shimada, Masahiko ^a   Ohsawa, Masahiro ^a  

^a HOSHI UNIVERSITY   (Japan)

^b Mine Pharmacy   (Japan)

Author keywords

Antidepressant; Aripiprazole; Glucose tolerance

Indexed keywords

ARIPIPRAZOLE; FLUOXETINE; GLUCOSE; OLANZAPINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE TIME EFFECT RELATION; DRUG POTENTIATION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; IMMOBILIZATION STRESS; MALE; MOUSE; NONHUMAN;

EID: 56649111416     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08201SC     Document Type: Article

References (15)

1. Robertson MM, Trimble MR. Major tranquillisers used as antidepressants: a review. J Affect Disord. 1982;4:173-193.
2. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158:131-134.
3. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63:763-771.
4. 2 receptor antagonistic activity. J Pharmacol Exp Ther. 1995;274:329-336.
5. 1A receptor. Eur J Pharmacol. 2002;441:137-140.
6. Papakostas GI, Petersen TJ, Kinrys G, Burns AM, Worthington JJ, Alpert JE, et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry. 2005;66:1326-1330.
7. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
8. Kamei J, Miyata S, Morita K, Saitoh A, Takeda H. Effects of selective serotonin reuptake inhibitors on immobility time in the tail suspension test in streptozotocin-induced diabetic mice. Pharmacol Biochem Behav. 2003;75:247-254.
9. 1A receptor in the mouse tail suspension test. Neuropsychopharmacology. 2004;29:461-469.
10. Zocchi A, Fabbri D, Heidbreder CA. Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neurosci Lett. 2005;387:157-161.
11. Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology. 2007;32:289-297.
12. 1-adrenoceptors in the antidepressant-like effect of chlorpheniramine in the mouse tail suspension test. Eur J Pharmacol. 2007;562:72-76.
13. Ago Y, Harasawa T, Itoh S, Nakamura S, Baba A, Matsuda T. Antidepressant-like effect of coadministration of sulpiride and fluvoxamine in mice. Eur J Pharmacol. 2005;520:86-90.
14. Sacher J, Mossaheb N, Spindelegger C, Klein N, Geiss-Granadia T, Sauermann R, et al. Effects of olanzapine and siprasidone on glucose tolerance in healthy volunteers. Neuropsychopharmacology. 2008;33:1633-1641.
15. 1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A. 2007;104:3456-3459.